Checked
Biogen Inc.
Nasdaq: BIIB · Biological Products, (No Diagnostic Substances) · Cambridge, MA
- Revenue
- $9.89B
- +2.2% vs. prior year
- Net income
- $1.29B
- 13.1% net margin
- Total assets
- $29.44B
- Diluted EPS
- $8.79
Company details
As reported to the SEC
- SEC CIK
- 875045
- Stock
- Nasdaq: BIIB
- Legal Entity Identifier (LEI)
- W8J5WZB5IY3K0NDQT671
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- Headquarters
- 225 Binney Street, Cambridge, MA 02142
- Incorporated in
- Delaware
- Fiscal year end (SEC record)
- December 31
- Filer status
- Large accelerated filer
- Phone
- (617) 679-2000
- Employer ID (EIN)
- 33-0112644
- Last annual report
- 02/06/2026
- Last quarterly report
- 07/29/2026
Formerly: BIOGEN IDEC INC. (until 03/20/2015); BIOGEN IDEC INC (until 04/25/2007); IDEC PHARMACEUTICALS CORP / DE (until 11/12/2003); IDEC PHARMACEUTICALS CORP / CA (until 02/14/1997)
Annual financials
U.S. dollars, as tagged in each annual report's XBRL data. Later restatements replace earlier numbers. Select a date to open the filing.
| Fiscal year ended | 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 |
|---|---|---|---|---|---|
| Revenue | $9.89B | $9.68B | $9.84B | $10.17B | $10.98B |
| Operating income | Not reported | Not reported | Not reported | Not reported | $2.84B |
| Net income | $1.29B | $1.63B | $1.16B | $3.05B | $1.56B |
| Diluted earnings per share | $8.79 | $11.18 | $7.97 | $20.87 | $10.40 |
| Research and development | $1.78B | $1.98B | $2.45B | $2.23B | $2.5B |
| Total assets | $29.44B | $28.05B | $26.84B | $24.55B | $23.88B |
| Total liabilities | $11.18B | $11.33B | $12.05B | $11.17B | $12.92B |
| Shareholders' equity | $18.26B | $16.72B | $14.8B | $13.4B | $10.9B |
| Cash and cash equivalents | $3.01B | $2.38B | $1.05B | $3.42B | $2.26B |
| Long-term debt | $6.29B | $6.3B | $6.94B | $6.28B | $6.27B |
| Cash from operations | $2.2B | $2.88B | $1.55B | $1.38B | $3.64B |
| Capital expenditures | $153.8M | $153.7M | $277M | $240.3M | $258.1M |
Federal and state records filed under the name Biogen Inc.
Matched by the company name and by the subsidiary names it lists in SEC filings and other public records, after removing endings like Inc., Corp. and Holdings. Records marked Subsidiary were filed under a subsidiary name. A subsidiary that is not listed in those records is not included, and an unrelated business with the same name can appear.
Work visa sponsorship
Certified H-1B and PERM green card filings with the Department of Labor
| Employer on filing | H-1B | PERM |
|---|---|---|
| Biogen, Inc.Cambridge, MA | 60 | 6 |
FDA recalls
Recalls of food, drugs and devices reported to the FDA
Swipe the table sideways to see more columns.
Trucking registrations
Motor carrier registrations with the Federal Motor Carrier Safety Administration
Swipe the table sideways to see more columns.
| Carrier | USDOT | Power units |
|---|---|---|
| Biogen IncValley Mills, TX | 2051252 | 2 |
| Biogen Idec IncSan Diego, CA | 2663806 | 2 |
| Biogen IncCanyon Country, CA | 2773446 | 1 |
Subsidiaries
87 companies that Biogen Inc. owns or controls, as listed in its SEC annual report (Exhibit 21), GLEIF ownership records or USAspending
| Subsidiary | Listed in |
|---|---|
| Alcyone Therapeutics, Inc. | SEC 10-K |
| BIIB Colombia S.A.S. | SEC 10-K |
| BIOGEN INTERNATIONAL GMBH | GLEIF, SEC 10-K |
| BIOGEN MA INC. | GLEIF, SEC 10-K |
| Biogen (Argentina) SRL | SEC 10-K |
| Biogen (Bermuda) Technologies Ltd. | SEC 10-K |
| Biogen (Czech Republic) s.r.o. | SEC 10-K |
| Biogen (Denmark) A/S | SEC 10-K |
| Biogen (RTP) Realty LLC | SEC 10-K |
| Biogen Arabia Limited | SEC 10-K |
| Biogen Australia PTY Ltd | SEC 10-K |
| Biogen Austria GmbH | SEC 10-K |
| Biogen B.V. | SEC 10-K |
| Biogen Belgium | GLEIF |
| Biogen Belgium N.V./S.A. | SEC 10-K |
| Biogen Biotechnology (Shanghai) Co., Ltd | SEC 10-K |
| Biogen Brasil Produtos Farmaceuticos LTDA | SEC 10-K |
| Biogen Canada Inc. | SEC 10-K |
| Biogen Capability Center India Private Limited | SEC 10-K |
| Biogen Chesapeake LLC | SEC 10-K |
| Biogen Chile SpA | SEC 10-K |
| Biogen Digital Health Global LLC | SEC 10-K |
| Biogen Digital Health Inc. | SEC 10-K |
| Biogen Digital Health International GmbH | SEC 10-K |
| Biogen Distribution Services Limited | SEC 10-K |
| Biogen Estonia OU | SEC 10-K |
| Biogen Finland OY | SEC 10-K |
| Biogen Foundation Inc. | SEC 10-K |
| Biogen France S.A.S. | SEC 10-K |
| Biogen Holding I LLC | SEC 10-K |
| Biogen Holding II LLC | SEC 10-K |
| Biogen Hong Kong Limited | SEC 10-K |
| Biogen Hungary KFT | SEC 10-K |
| Biogen Idec (Ireland) Ltd. | SEC 10-K |
| Biogen Idec Biotech India Pvt. Ltd. | SEC 10-K |
| Biogen Idec Research Ltd. | SEC 10-K |
| Biogen Idec Uruguay SA | SEC 10-K |
| Biogen International Neuroscience GmbH | SEC 10-K |
| Biogen Italia S.R.L. | SEC 10-K |
| Biogen Japan Ltd. | SEC 10-K |
| Biogen Korea LLC | SEC 10-K |
| Biogen Latvia SIA | SEC 10-K |
| Biogen Lithuania UAB | SEC 10-K |
| Biogen Luxembourg Holding S.a.r.l. | SEC 10-K |
| Biogen Management Services GmbH | SEC 10-K |
| Biogen Manufacturing Holding LLC | SEC 10-K |
| Biogen Mexico S. de R.L. de C.V. | SEC 10-K |
| Biogen NZ Biopharma Ltd. | SEC 10-K |
| Biogen Netherlands B.V. | SEC 10-K |
| Biogen New Ventures Inc. | SEC 10-K |
| Biogen Norway AS | SEC 10-K |
| Biogen OUS Holding Inc. | SEC 10-K |
| Biogen Pharma d.o.o. | SEC 10-K |
| Biogen Pharma, farmacevtska in biotehnoloska druzba, d.o.o. | SEC 10-K |
| Biogen Poland Sp. z.o.o. | SEC 10-K |
| Biogen Portugal Sociedade Farmaceutica, Unipessoal Lda. | SEC 10-K |
| Biogen Realty Corporation | SEC 10-K |
| Biogen Realty Limited Partnership | SEC 10-K |
| Biogen Regional Headquarters LLC | SEC 10-K |
| Biogen SRO Inc. | SEC 10-K |
| Biogen Slovakia s.r.o. | SEC 10-K |
| Biogen Spain, S.L. | SEC 10-K |
| Biogen Sweden AB | SEC 10-K |
| Biogen Switzerland AG | SEC 10-K |
| Biogen Taiwan Limited | SEC 10-K |
| Biogen Therapeutics Inc. | SEC 10-K |
| Biogen Turkey Ilac Ticaret Limited Sirketi | SEC 10-K |
| Biogen U.S. Corporation | SEC 10-K |
| Biogen U.S. Limited Partnership | SEC 10-K |
| Biogen U.S. Pacific LLC | SEC 10-K |
| Biogen U.S. West Corporation | SEC 10-K |
| Conforma Therapeutics Corporation | SEC 10-K |
| Convergence Pharmaceuticals Limited | SEC 10-K |
| Eidetica Biopharma GmbH | SEC 10-K |
| Human Immunology Biosciences, Inc. | SEC 10-K |
| NightstaRx Limited | SEC 10-K |
| Nightstar Europa Limited | SEC 10-K |
| Nightstar Therapeutics Limited | SEC 10-K |
| Nightstar, Inc. | SEC 10-K |
| Old Convergence Pharmaceuticals Limited | SEC 10-K |
| Reata Germany GmbH | SEC 10-K |
| Reata Pharmaceuticals Global, Inc. | SEC 10-K |
| Reata Pharmaceuticals Holdings, LLC. | SEC 10-K |
| Reata U.K. Limited | SEC 10-K |
| Silver Acquisition Co. Ltd. | SEC 10-K |
| Stromedix, LLC | SEC 10-K |
| Tungsten Bidco Limited | SEC 10-K |
Recent filings
130 recent filings on record; insider ownership forms (3, 4, 5 and 144) are not listed here
Swipe the table sideways to see more columns.
43 insider ownership reports (Forms 3, 4, 5 and 144) were filed about Biogen Inc. in the last 12 months. They list trades by officers, directors and large holders; see them on SEC EDGAR.
Other biological products, (no diagnostic substances)
Swipe the table sideways to see more columns.
| Company | Headquarters | Revenue | Net income |
|---|---|---|---|
| Amgen IncAMGN | Thousand Oaks, CA | $36.75B | $7.71B |
| Gilead Sciences, Inc.GILD | Foster City, CA | $29.44B | $8.51B |
| Neurocrine Biosciences IncNBIX | San Diego, CA | $2.86B | $478.6M |
| Exelixis, Inc.EXEL | Alameda, CA | $2.32B | $782.6M |
| Qiagen N.V.QGEN | Pl Venlo, Netherlands | $2.09B | $424.9M |
| Moderna, Inc.MRNA | Cambridge, MA | $1.94B | -$2.82B |
| Halozyme Therapeutics, Inc.HALO | San Diego, CA | $1.4B | $316.9M |
| BIO-TECHNE CorpTECH | Minneapolis, MN | $1.22B | $181.9M |
Profile refreshed Oct 26, 2026; financials refreshed Oct 22, 2026.
Frequently asked questions
- What is Biogen Inc.'s CIK number?
- Biogen Inc.'s SEC Central Index Key (CIK) is 875045.
- What is Biogen Inc.'s stock ticker?
- Biogen Inc. trades as Nasdaq: BIIB.
- What was Biogen Inc.'s revenue?
- Biogen Inc. reported revenue of $9.89B for the fiscal year ended Dec 31, 2025, +2.2% from the year before.
- When does Biogen Inc.'s fiscal year end?
- Biogen Inc.'s fiscal year end on file with the SEC is December 31; its most recent fiscal year ended Dec 31, 2025.
- Where is Biogen Inc. headquartered?
- Biogen Inc.'s principal executive office on file with the SEC is in Cambridge, MA.
- What companies does Biogen Inc. own?
- Biogen Inc. lists 87 subsidiaries in its SEC filings and other public records, including Alcyone Therapeutics, Inc., BIIB Colombia S.A.S., BIOGEN INTERNATIONAL GMBH.
- Does Biogen Inc. sponsor H-1B visas?
- Department of Labor records show 60 certified H-1B filings and 6 certified PERM filings under the name Biogen Inc.
- Has Biogen Inc. had any FDA recalls?
- The FDA lists 2 recalls with Biogen Inc. as the recalling firm. The latest started Dec 9, 2020.
Source: U.S. Securities and Exchange Commission, EDGAR submissions and XBRL company facts · Last updated 10/26/2026